- Global Pharma News & Resources

aap: Successful completion of capital increase with subscription rights with gross issuing proceeds of around EUR 3.5 million

DGAP-News: aap Implantate AG / Key word(s): Capital Increase/Financing

10.05.2019 / 15:51
The issuer is solely responsible for the content of this announcement.

The information contained in this announcement is not intended for publication or distribution in or within the United States of America, Australia, Canada or Japan.

aap Implantate AG ("aap") successfully completed the capital increase with subscription rights out of authorised capital resolved on 17 April 2019. aap's share capital is increased by issuing a total of 3,360,467 new no-par value bearer shares against cash contributions by EUR 3,360,467.00 from EUR 28,706,910.00 to EUR 32,067,377.00. Based on the determined subscription price of EUR 1.04 per new share the gross issuing proceeds are around EUR 3.5 million. The new shares are entitled to participate in dividends as of 1 January 2018.

"We are pleased about the successful capital increase and thank our shareholders for their trust," says Rubino Di Girolamo, Chairman of the Management Board / CEO at aap. "We intend to use the cash inflow from the capital increase to finance our planned sales growth and the human clinical study for our pioneering and innovative silver coating technology."

At all, 3,260,467 new shares were subscribed for by exercising subscription and oversubscription rights. They include the exercise by major existing shareholders who had committed themselves to subscribe for a total of 2,211,539 new shares ahead of the transaction. In addition, a total of 100,000 new shares, that were not subscribed for, were placed with qualified institutional investors by means of a private placement after the subscription period had expired.

With the cash inflow from the capital increase and two further external financings aap has
EUR 5.2 million at its disposal that the company will use to finance its planned sales growth and the further development of its pioneering and innovative silver coating technology.


This announcement constitutes neither an offer nor a solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan or any other jurisdiction in which an offer is unlawful.

This announcement is not an offer of securities for sale in the United States. Securities may be offered or sold in the United States only upon prior registration or upon exemption from the obligation of prior registration pursuant to the Securities Act. If a public offering of securities were to take place in the United States, it would be effected by means of a securities prospectus which investors could obtain from the Company. This prospectus would contain detailed information about the Company and its management, as well as financial information. There will be no public offering of the securities referred to in this announcement in the United States.

Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to or for the account of persons resident in Australia, Canada or Japan.

Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290;

10.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 809895

End of News DGAP News Service

Editor Details

Last Updated: 10-May-2019